Latest news on Laboratorytalk categorised by product type
Antibodies
Archive page 3 of 8
Our RSS feed for Antibodies press releases
Collaborative programme on wound healing
Oxford BioMedica has used its Focused Target Identification platform to identify an enzyme that is central to the control of blood vessel growth, an essential feature of effective wound healing
News from Oxford BioMedica ( 4 August 2006)
Research and development deal with Intervet Pharma
Oxford BioMedica and Intervet Pharma R+D announced in January 2003 that they had signed a research agreement for the development of TroVax-Vet
News from Oxford BioMedica ( 4 August 2006)
Funding from the Foundation Fighting Blindness
Oxford BioMedica announced that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has agreed to fund preclinical proof-of-principle studies for vision-loss product RetinoStat
News from Oxford BioMedica ( 2 August 2006)
MoNuDin in the treatment of motor neuron disease
Oxford BioMedica presented 'promising' preclinical data from its motor neuron disease programme at two major international conferences in November 2003
News from Oxford BioMedica ( 2 August 2006)
Metxia enters clinical trials in pancreatic cancer
Oxford BioMedica received approval from the UK's Gene Therapy Advisory Committee (GTAC) for MetXia to enter a two-stage Phase I/II clinical trial in patients with pancreatic cancer
News from Oxford BioMedica ( 2 August 2006)
Oxford Biomedica acquires Chiron patents
Oxford BioMedica has signed an agreement with Chiron to acquire certain patent families from Chiron's gene therapy patent portfolio
News from Oxford BioMedica ( 1 August 2006)
Scientists pioneer motor neuron disease treatment
Amyotrophic Lateral Sclerosis (ALS), the most prevalent form of motor neuron disease, causes adult-onset, progressive motor neuron degeneration in the brain and spinal cord
News from Oxford BioMedica ( 1 August 2006)
FDA approval for trial of Trovax in renal cancer
The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application to evaluate TroVax, a proprietary cancer vaccine, in patients with metastatic renal cancer
News from Oxford BioMedica ( 1 August 2006)
Grant from UK gene therapy research programme
The UK Department of Health has awarded Oxford BioMedica £0.5 million to develop its proprietary LentiVector technology for use in the treatment of single gene inherited disorders
News from Oxford BioMedica ( 1 August 2006)
LentiVector licensing agreement with Merck
Oxford BioMedica has signed a licence agreement for its LentiVector technology with Merck
News from Oxford BioMedica ( 1 August 2006)
Phase II trial with TroVax in colorectal cancer
Oxford BioMedica announces that Cancer Research UK has received approval to start a Phase II trial with TroVax in Colorectal Cancer
News from Oxford BioMedica ( 1 August 2006)
Cytochrome P450 enzymes in cancer gene therapy
Oxford BioMedica has signed an agreement with Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute extending exclusive access to cytochrome P450 enzymes in cancer therapy
News from Oxford BioMedica (31 July 2006)
Positive results with Trovax in colorectal cancer
Oxford BioMedica announced that primary endpoints have been achieved at the interim stage of two Phase II trials in patients with Stage IV colorectal cancer receiving TroVax alongside chemotherapy
News from Oxford BioMedica (31 July 2006)
Lentivector for avian transgenics biomanufacturing
Oxford BioMedica and Viragen announced a license agreement for Oxford BioMedica's LentiVector gene delivery technology
News from Oxford BioMedica (31 July 2006)
Lentivector success in avian transgenics
Article reports data that demonstrate Oxford BioMedica's lentiviral vectors can be used to generate transgenic lines with an efficiency of the order of 10 to 100-fold higher than any previous method
News from Oxford BioMedica (31 July 2006)
Oxford Biomedica - Innurex programme
Oxford BioMedica is announcing that its Innurex programme for nerve regeneration in spinal cord injury has been awarded $150,000 from the Christopher Reeve Paralysis Foundation
News from Oxford BioMedica (31 July 2006)
Lentivector licensing agreement signed
Oxford BioMedica has signed a further licence agreement for its LentiVector technology with a large biopharmaceutical company
News from Oxford BioMedica (28 July 2006)
Lentivector licensing agreement with Biogen Idec
Oxford BioMedica has entered into an agreement to license its LentiVector technology to Biogen Idec for use in research activities
News from Oxford BioMedica (28 July 2006)
Potential for treatment of spinal muscular atrophy
Oxford Biomedica publishes 'promising' preclinical efficacy results with its product candidate smn1-g for spinal muscular atrophy
News from Oxford BioMedica (28 July 2006)
Ex vivo gene technology licensed to Molmed
Oxford BioMedica and MolMed have announced a licence agreement for Oxford BioMedica's retroviral ex vivo gene delivery technology
News from Oxford BioMedica (28 July 2006)
Earlier news from this category...
Latest news from this category...
